Your browser doesn't support javascript.
loading
Audiometric and Otologic Findings in Children and Young Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas.
Idowu, Victoria; Christensen, Julie; Gross, Andrea M; Dombi, Eva; Miles, Jennifer R; King, Kelly; Chisholm, Jennifer; Zalewski, Christopher; Baldwin, Andrea; Whitcomb, Patricia; Burgess, Crystal; Widemann, Brigitte C; Brewer, Carmen C; Kim, Hung Jeffrey.
Affiliation
  • Idowu V; Audiology Unit, Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA.
  • Christensen J; Audiology Unit, Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA.
  • Gross AM; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Dombi E; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Miles JR; Department of Otolaryngology-Head and Neck Surgery, Georgetown University Hospital, Washington, DC, USA.
  • King K; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Chisholm J; Audiology Unit, Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA.
  • Zalewski C; Audiology Unit, Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA.
  • Baldwin A; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Whitcomb P; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Burgess C; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Widemann BC; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Brewer CC; Audiology Unit, Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA.
  • Kim HJ; Department of Otolaryngology-Head and Neck Surgery, Georgetown University Hospital, Washington, DC, USA.
Laryngoscope ; 133(10): 2770-2778, 2023 10.
Article in En | MEDLINE | ID: mdl-36583617
OBJECTIVES: To characterize otologic and audiologic manifestations in our NF1 cohort and explore the relationship between otologic and audiologic findings in a subset of patients with ear-related plexiform neurofibromas (PNs). METHODS: Audiologic and otologic clinical evaluations were conducted on 102 patients with NF1 in a natural history study (5-45 years; M = 14.4 years; Mdn = 14). Testing included pure tone and speech audiometry, middle ear function, neurodiagnostic auditory brainstem response (ABR), auditory processing, and MRIs of the head and neck region. Patients referred to this study had an overall higher incidence and burden of PNs than the overall NF1 population. RESULTS: The majority of subjects in this cohort had normal hearing sensitivity (81%) and normal middle ear function (78%). Nineteen participants had hearing loss that ranged in degree from mild to profound, with the majority in the mild range. Hearing loss was twice as likely to be conductive than sensorineural. In patients with ear-related PNs (n = 12), hearing loss was predominantly conductive (60%). Seventy-five percent of ears with PNs had atypical tympanometric tracings that could not be characterized by the classic categories. In all 20 patients with a PN in the temporal bone, the ear canal was affected, and the PNs often extended to the surrounding soft tissue regions. CONCLUSIONS: People with NF1-related PNs in the temporal bone and adjacent skull base should have audiometric and otologic monitoring. Addressing hearing concerns should be part of routine clinical evaluations in patients with NF1. Magnetic resonance imaging (MRI) should be performed in patients with NF1 who have hearing loss. LEVEL OF EVIDENCE: 3 Laryngoscope, 133:2770-2778, 2023.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neurofibromatosis 1 / Neurofibroma, Plexiform / Deafness / Hearing Loss Type of study: Diagnostic_studies Limits: Adult / Child / Humans Language: En Journal: Laryngoscope Journal subject: OTORRINOLARINGOLOGIA Year: 2023 Document type: Article Affiliation country: United States Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neurofibromatosis 1 / Neurofibroma, Plexiform / Deafness / Hearing Loss Type of study: Diagnostic_studies Limits: Adult / Child / Humans Language: En Journal: Laryngoscope Journal subject: OTORRINOLARINGOLOGIA Year: 2023 Document type: Article Affiliation country: United States Country of publication: United States